Does analysis using "last observation carried forward" introduce bias in dementia research?

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 8, 2008, Pages 751-753

  Molnar, Frank J ^a,b,e   Hutton, Brian ^c   Fergusson, Dean ^c,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BRUYÈRE RESEARCH INSTITUTE   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO;

ANALYTIC METHOD; CLINICAL TRIAL; DEMENTIA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG USE; FALSE POSITIVE RESULT; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL RESEARCH; NOTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROBABILITY; SENSITIVITY ANALYSIS;

EID: 54349127108     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080820     Document Type: Note

References (15)

1. Unnebrink K, Windeler J. Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 2001;20:3931-46.
2. Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev 2003;4:175-84.
3. Mallinckrodt CH, Clark WS, Carroll RJ, et al. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 2003;13:179-90.
4. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21.
5. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000;54:588-92.
6. Hills R, Gray R, Stowe R. Drop-out bias undermines findings of improved functionality with cholinesterase inhibitors. Neurobiol Aging 2002;23(Suppl 1):S89.
7. Lanctôt KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64.
8. Aisen PS, Schafer KA, Grundman M, et al. Effects of refocoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
9. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7.
10. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27.
11. Hogan DB. Donepezil for severe Alzheimer's disease. Lancet 2006;367:1031-2.
12. Committee for Proprietary Medicinal Products. Points to consider on missing data. London (UK): European Agency for the Evaluation of Medicinal Products; 2001. Available: www.emea.europa.eu/pdfs/human/ewp/177699EN.pdf (accessed 2008 July 24).
13. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 2002;47:68-75.
14. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88.
15. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.